# Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

> **NCT06567015** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 171 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** STX-241

## Key facts

- **NCT ID:** NCT06567015
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-17
- **Primary completion:** 2027-11-20
- **Final completion:** 2030-07
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567015, "Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06567015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*